Skip to content

enGene Therapeutics Inc.

ENGN ENGNW

CIK 0001980845 · Biological Products, (No Diagnostic Substances) · Nasdaq, Nasdaq

  • enGene Holdings Inc. (until 2026-03-09)
← back to feed
Revenue (TTM)
—
Q2 Jun 2026
Net Income (TTM)
−$114.79M
−112.7% YoY Q2 Jun 2026
EPS Diluted (TTM)
$0.07
+56.8% YoY Q2 Jun 2026
Gross Margin
—
Q2 Jun 2026
Operating Margin
—
Q2 Jun 2026
Net Margin
—
Q2 Jun 2026
Free Cash Flow (TTM)
−$69.16M
Q2 Jun 2026
Cash
$29.83M
Q2 Jun 2026
Total Debt
—
Q2 Jun 2026
Shares Outstanding
66.99M sh
Q2 Jun 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings